p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids)

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 39

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Oct 21, 2006; 12(39): 6280-6284
Published online Oct 21, 2006. doi: 10.3748/wjg.v12.i39.6280

Table 2 Accompanying histopathologic features

Pathology	Patients (n)	Rate (%)
Atrophy	8	50.0
Neuroendocrine hyperplasia	7	43.8
Intestinal metaplasia	9	56.3
Neuroendocrine dysplasia	3	18.8
Multifocality	5	31.4
Submucosal extension	8	50.0

Citation: Doganavsargil B, Sarsik B, Kirdok FS, Musoglu A, Tuncyurek M. p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids). World J Gastroenterol 2006; 12(39): 6280-6284
URL: https://www.wjgnet.com/1007-9327/full/v12/i39/6280.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i39.6280

Doganavsargil B, Sarsik B, Kirdok FS, Musoglu A, Tuncyurek M. p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids). World J Gastroenterol 2006; 12(39): 6280-6284 [PMID: 17072949 DOI: 10.3748/wjg.v12.i39.6280]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.